U.K. Biotechnology & Pharmaceutical Services Outsourcing Market Size, Share & Trends Analysis Report By Service (Consulting, Regulatory Affairs), By End-use (Pharma, Biotech), And Segment Forecasts, 2021 - 2028
This report can be delivered to the clients within 48 Business Hours
U.K. Biotechnology & Pharmaceutical Services Outsourcing Market Growth & Trends
The U.K. biotechnology and pharmaceutical services outsourcing market size is expected to reach USD 4.1 billion by 2028, according to a new report by Grand View Research, Inc. The market is expected to expand at a CAGR of 6.9% from 2021 to 2028. This is due to the change in the regulatory landscape and increased outsourcing of R&D activities. Pharma and biotech companies are outsourcing regulatory affairs services to CROs, which helps them focus on core competencies. Outsourcing helps in reducing variable costs, which in turn enables geographic expansion. Regulatory support activities include regulatory intelligence, product labeling, regulatory document submissions, liaison with regulatory authorities, and planning regulatory strategies. Increasing requirements of the complex regulatory documentation processes and the high cost related to clinical trials have led to the shift from in-house management of regulatory affairs to outsourcing to CROs.
However, the covid-19 pandemic would have a long-term impact on biopharmaceutical manufacturing. Traditional vaccinations are too time-consuming and complex to produce. They are not vertically scalable, and they pose a safety risk. Advanced vaccines, on the other hand, are extremely safe and can quickly and effectively respond to viruses with high pandemic potential and high fatality rates.The demand for advanced vaccines, in particular, would have an impact on the biopharmaceutical industry's growth after COVID-19. The additional vaccine production capacity would force developers to reconsider items that were previously deemed too costly to manufacture.
U.K. Biotechnology & Pharmaceutical Services Outsourcing Market Report Highlights
U.K. Biotechnology & Pharmaceutical Services Outsourcing Market Growth & Trends
The U.K. biotechnology and pharmaceutical services outsourcing market size is expected to reach USD 4.1 billion by 2028, according to a new report by Grand View Research, Inc. The market is expected to expand at a CAGR of 6.9% from 2021 to 2028. This is due to the change in the regulatory landscape and increased outsourcing of R&D activities. Pharma and biotech companies are outsourcing regulatory affairs services to CROs, which helps them focus on core competencies. Outsourcing helps in reducing variable costs, which in turn enables geographic expansion. Regulatory support activities include regulatory intelligence, product labeling, regulatory document submissions, liaison with regulatory authorities, and planning regulatory strategies. Increasing requirements of the complex regulatory documentation processes and the high cost related to clinical trials have led to the shift from in-house management of regulatory affairs to outsourcing to CROs.
However, the covid-19 pandemic would have a long-term impact on biopharmaceutical manufacturing. Traditional vaccinations are too time-consuming and complex to produce. They are not vertically scalable, and they pose a safety risk. Advanced vaccines, on the other hand, are extremely safe and can quickly and effectively respond to viruses with high pandemic potential and high fatality rates.The demand for advanced vaccines, in particular, would have an impact on the biopharmaceutical industry's growth after COVID-19. The additional vaccine production capacity would force developers to reconsider items that were previously deemed too costly to manufacture.
U.K. Biotechnology & Pharmaceutical Services Outsourcing Market Report Highlights
- The consulting services segment dominated the market and accounted for the largest revenue share of 22.7% in 2020. This is due to an increase in the demand for CRO consultants in the industry
- The regulatory affairs segment is anticipated to register a lucrative CAGR of 7.9% over the forecast period
- The pharmaceutical companies segment held the largest revenue share of 54.6% in 2020. The increasing R&D investments are a factor supporting market growth. The pharmaceutical R&D accounted for 27.0% of all the U.K. manufacturing R&D
- The biotechnology companies segment is projected to witness the fastest growth rate of 7.3% over the forecast period. This is due to a lack of capacity and capability in completing regulatory affairs responsibilities, as well as the presence of severe regulatory standards in developed countries
CHAPTER 1 METHODOLOGY AND SCOPE
1.1 Market Segmentation & Scope
1.1.1 Estimates And Forecast Timeline
1.2 Research Methodology
1.3 Information Procurement
1.3.1 Purchased Database
1.3.2 Gvr’s Internal Database
1.3.3 Secondary Sources
1.3.4 Primary Research
1.3.5 Details Of Primary Research
1.4 Information Or Data Analysis
1.4.1 Data Analysis Models
1.5 Market Formulation & Validation
1.6 Region Wise Market Calculation
1.6.1 Region Wise Market: Base Estimates
1.6.2 Global Market: CAGR Calculation
1.7 List of Secondary Sources
1.8 Objectives
1.8.1 Objective - 1: Understanding market dynamics
1.8.2 Objective - 2: Understanding market estimates and forecasts
1.8.3 Objective - 3: Understanding attributes such as strategy framework and competitor categorization
1.8.4 Objective - 4: Understanding the key service and application scopes to conclude on the market size.
CHAPTER 2 EXECUTIVE SUMMARY
2.1 Market Outlook
CHAPTER 3 U.K. BIOTECHNOLOGY & PHARMACEUTICAL SERVICE OUTSOURCING MARKET: VARIABLES, TRENDS, & SCOPE
3.1 Market Segmentation and Scope
3.2 Market Dynamics
3.2.1 Market Driver Analysis
3.2.1.1 Increasing outsourcing of R&D activities
3.2.1.2 Changing regulatory landscape
3.2.1.3 Growing drug development costs coupled with high clinical development failure rates
3.2.1.5 Increasing mergers and collaborations
3.2.2 Market Restraint Analysis
3.2.2.1 Monitoring issues and lack of standardization
3.2.2.2 Loss of control
3.2.2.3 Data security issues
3.3 Penetration & Growth Prospect Mapping
3.4 COVID - 19 Impact on the Market
3.5 Major Deals and Strategic Alliances Analysis
3.6 U.K. Biotechnology & Pharmaceutical Service Outsourcing: Market Analysis Tools
3.6.1 Industry Analysis - Porter’s
3.6.3 PESTEL Analysis
CHAPTER 4 U.K. BIOTECHNOLOGY & PHARMACEUTICAL SERVICE OUTSOURCING MARKET: SERVICE SEGMENT ANALYSIS
4.1 U.K. Biotechnology & Pharmaceutical Service Outsourcing Market: Service Market Share Analysis, 2020 & 2028
4.2 Consulting Services
4.2.1 Consulting Services Market, 2016 - 2028 (USD Million)
4.3 Auditing & assessment
4.3.1 Auditing & assessment Market, 2016 - 2028 (USD Million)
4.4 Regulatory affairs
4.4.1 Regulatory affairs Market, 2016 - 2028 (USD Million)
4.5 Product maintenance
4.5.1 Product maintenance Market, 2016 - 2028 (USD Million)
4.6 Product design & development
4.6.1 Product design & development Market, 2016 - 2028 (USD Million)
4.7 Product testing & validation
4.7.1 Product testing & validation Market, 2016 - 2028 (USD Million)
4.8 Training & education
4.8.1 Training & education Market, 2016 - 2028 (USD Million)
4.9 Others
4.9.1 Others Market, 2016 - 2028 (USD Million)
CHAPTER 5 U.K. BIOTECHNOLOGY & PHARMACEUTICAL SERVICE OUTSOURCING MARKET: END USE SEGMENT ANALYSIS
5.1 U.K. Biotechnology & Pharmaceutical Service Outsourcing Market: End - use Market Share Analysis, 2020 & 2028
5.2 Pharmaceutical
5.2.1 Pharmaceutical Market, 2016 - 2028 (USD Million)
5.3 Biotech
5.3.1 Biotech Market, 2016 - 2028 (USD Million)
CHAPTER 6 COMPANY PROFILES
6.1 The Quantic Group
6.1.1 Company Overview
6.1.2 Service Benchmarking
6.1.3 Financial Performance
6.1.4 Strategic Initiatives
6.2 Iqvia Holdings, Inc
6.2.1 Company Overview
6.2.2 Financial Performance
6.2.3 Service Benchmarking
6.2.4 Strategic Initiatives
6.3 Parexel International Corporation
6.3.1 Company Overview
6.3.2 Service Benchmarking
6.3.3 Strategic Initiatives
6.4 Lachman Consultant Services
6.4.1 Company Overview
6.4.2 Financial Performance
6.4.3 Service Benchmarking
6.5 GMP Pharmaceuticals
6.5.1 Company Overview
6.5.2 Financial Performance
6.5.3 Service Benchmarking
6.6 Concept Heidelberg GmbH
6.6.1 Company Overview
6.6.2 Financial Performance
6.6.3 Service Benchmarking
6.7 Covance, INC.
6.7.1 Company Overview
6.7.2 Financial Performance
6.7.3 Service Benchmarking
6.7.4 Strategic Initiatives
6.8 PRA Health Sciences
6.8.1 Company Overview
6.8.2 Financial Performance
6.8.3 Service Benchmarking
6.9 Charles River Laboratories
6.9.1 Company Overview
6.9.2 Financial Performance
6.9.3 Service Benchmarking
6.9.4 Strategic Initiatives
6.10 ICON plc
6.10.1 Company Overview
6.10.2 Financial Performance
6.10.3 Service Benchmarking
6.10.4 Strategic Initiatives
1.1 Market Segmentation & Scope
1.1.1 Estimates And Forecast Timeline
1.2 Research Methodology
1.3 Information Procurement
1.3.1 Purchased Database
1.3.2 Gvr’s Internal Database
1.3.3 Secondary Sources
1.3.4 Primary Research
1.3.5 Details Of Primary Research
1.4 Information Or Data Analysis
1.4.1 Data Analysis Models
1.5 Market Formulation & Validation
1.6 Region Wise Market Calculation
1.6.1 Region Wise Market: Base Estimates
1.6.2 Global Market: CAGR Calculation
1.7 List of Secondary Sources
1.8 Objectives
1.8.1 Objective - 1: Understanding market dynamics
1.8.2 Objective - 2: Understanding market estimates and forecasts
1.8.3 Objective - 3: Understanding attributes such as strategy framework and competitor categorization
1.8.4 Objective - 4: Understanding the key service and application scopes to conclude on the market size.
CHAPTER 2 EXECUTIVE SUMMARY
2.1 Market Outlook
CHAPTER 3 U.K. BIOTECHNOLOGY & PHARMACEUTICAL SERVICE OUTSOURCING MARKET: VARIABLES, TRENDS, & SCOPE
3.1 Market Segmentation and Scope
3.2 Market Dynamics
3.2.1 Market Driver Analysis
3.2.1.1 Increasing outsourcing of R&D activities
3.2.1.2 Changing regulatory landscape
3.2.1.3 Growing drug development costs coupled with high clinical development failure rates
3.2.1.5 Increasing mergers and collaborations
3.2.2 Market Restraint Analysis
3.2.2.1 Monitoring issues and lack of standardization
3.2.2.2 Loss of control
3.2.2.3 Data security issues
3.3 Penetration & Growth Prospect Mapping
3.4 COVID - 19 Impact on the Market
3.5 Major Deals and Strategic Alliances Analysis
3.6 U.K. Biotechnology & Pharmaceutical Service Outsourcing: Market Analysis Tools
3.6.1 Industry Analysis - Porter’s
3.6.3 PESTEL Analysis
CHAPTER 4 U.K. BIOTECHNOLOGY & PHARMACEUTICAL SERVICE OUTSOURCING MARKET: SERVICE SEGMENT ANALYSIS
4.1 U.K. Biotechnology & Pharmaceutical Service Outsourcing Market: Service Market Share Analysis, 2020 & 2028
4.2 Consulting Services
4.2.1 Consulting Services Market, 2016 - 2028 (USD Million)
4.3 Auditing & assessment
4.3.1 Auditing & assessment Market, 2016 - 2028 (USD Million)
4.4 Regulatory affairs
4.4.1 Regulatory affairs Market, 2016 - 2028 (USD Million)
4.5 Product maintenance
4.5.1 Product maintenance Market, 2016 - 2028 (USD Million)
4.6 Product design & development
4.6.1 Product design & development Market, 2016 - 2028 (USD Million)
4.7 Product testing & validation
4.7.1 Product testing & validation Market, 2016 - 2028 (USD Million)
4.8 Training & education
4.8.1 Training & education Market, 2016 - 2028 (USD Million)
4.9 Others
4.9.1 Others Market, 2016 - 2028 (USD Million)
CHAPTER 5 U.K. BIOTECHNOLOGY & PHARMACEUTICAL SERVICE OUTSOURCING MARKET: END USE SEGMENT ANALYSIS
5.1 U.K. Biotechnology & Pharmaceutical Service Outsourcing Market: End - use Market Share Analysis, 2020 & 2028
5.2 Pharmaceutical
5.2.1 Pharmaceutical Market, 2016 - 2028 (USD Million)
5.3 Biotech
5.3.1 Biotech Market, 2016 - 2028 (USD Million)
CHAPTER 6 COMPANY PROFILES
6.1 The Quantic Group
6.1.1 Company Overview
6.1.2 Service Benchmarking
6.1.3 Financial Performance
6.1.4 Strategic Initiatives
6.2 Iqvia Holdings, Inc
6.2.1 Company Overview
6.2.2 Financial Performance
6.2.3 Service Benchmarking
6.2.4 Strategic Initiatives
6.3 Parexel International Corporation
6.3.1 Company Overview
6.3.2 Service Benchmarking
6.3.3 Strategic Initiatives
6.4 Lachman Consultant Services
6.4.1 Company Overview
6.4.2 Financial Performance
6.4.3 Service Benchmarking
6.5 GMP Pharmaceuticals
6.5.1 Company Overview
6.5.2 Financial Performance
6.5.3 Service Benchmarking
6.6 Concept Heidelberg GmbH
6.6.1 Company Overview
6.6.2 Financial Performance
6.6.3 Service Benchmarking
6.7 Covance, INC.
6.7.1 Company Overview
6.7.2 Financial Performance
6.7.3 Service Benchmarking
6.7.4 Strategic Initiatives
6.8 PRA Health Sciences
6.8.1 Company Overview
6.8.2 Financial Performance
6.8.3 Service Benchmarking
6.9 Charles River Laboratories
6.9.1 Company Overview
6.9.2 Financial Performance
6.9.3 Service Benchmarking
6.9.4 Strategic Initiatives
6.10 ICON plc
6.10.1 Company Overview
6.10.2 Financial Performance
6.10.3 Service Benchmarking
6.10.4 Strategic Initiatives
LIST OF TABLES
Table 1 List of Secondary Sources
Table 2 List of Abbreviations
Table 3 U.K. Biotechnology & Pharmaceutical Services Outsourcing Market, by End Use, 2016 - 2028 (USD Million)
Table 4 U.K. Biotechnology & Pharmaceutical Services Outsourcing Market, by Service, 2016 - 2028 (USD Million)
Table 5 U.K. Biotechnology & Pharmaceutical Consulting Services Market, by Service, 2016 - 2028 (USD Million)
Table 6 U.K. Biotechnology & Pharmaceutical Regulatory Affairs Services Market, by Service, 2016 - 2028 (USD Million)
Table 1 List of Secondary Sources
Table 2 List of Abbreviations
Table 3 U.K. Biotechnology & Pharmaceutical Services Outsourcing Market, by End Use, 2016 - 2028 (USD Million)
Table 4 U.K. Biotechnology & Pharmaceutical Services Outsourcing Market, by Service, 2016 - 2028 (USD Million)
Table 5 U.K. Biotechnology & Pharmaceutical Consulting Services Market, by Service, 2016 - 2028 (USD Million)
Table 6 U.K. Biotechnology & Pharmaceutical Regulatory Affairs Services Market, by Service, 2016 - 2028 (USD Million)
LIST OF FIGURES
Fig. 1 Market research process
Fig. 2 Information procurement
Fig. 3 Primary research pattern
Fig. 4 Primary interviews in Europe
Fig. 5 Market research approaches
Fig. 6 QFD modeling for market share assessment
Fig. 7 Market formulation & validation
Fig. 8 Commodity flow analysis
Fig. 9 U.K. Biotechnology/pharmaceutical services outsourcing market snapshot (2020)
Fig. 10 U.K. Biotechnology/pharmaceutical services outsourcing market segmentation
Fig. 11 Market driver relevance analysis (Current & future impact)
Fig. 12 Pharmaceutical R&D spending, 2015-2024 (USD billion)
Fig. 13 Average cost per new drug development, 2000 - 2011 (USD Million)
Fig. 14 Failure rates in phase transitions during drug development
Fig. 15 Market restraint relevance analysis (Current & future impact)
Fig. 16 Penetration & growth prospect mapping
Fig. 17 Porter’s five forces analysis
Fig. 18 SWOT analysis, by factor (political & legal, economic and technological)
Fig. 19 Reasons behind outsourcing
Fig. 20 Percentage of outsourcing of different functions
Fig. 21 Selection parameters
Fig. 22 Heat map for pricing models opted by competitors
Fig. 23 Companies with affected trials, by size
Fig. 24 Affected trials, by study phase
Fig. 25 COVID-19 trials, 2020
Fig. 26 U.K. Biotechnology/pharmaceutical services outsourcing market stage outlook: Segment dashboard
Fig. 27 U.K. Biotechnology/pharmaceutical services outsourcing market: Service movement analysis
Fig. 28 Consulting market, 2016 - 2028 (USD Million)
Fig. 29 Regulatory compliance market, 2016 - 2028 (USD Million)
Fig. 30 Remediation market, 2016 - 2028 (USD Million)
Fig. 31 Quality management systems consulting market, 2016 - 2028 (USD Million)
Fig. 32 Others market, 2016 - 2028 (USD Million)
Fig. 33 Auditing and assessment market, 2016 - 2028 (USD Million)
Fig. 34 Regulatory affairs market, 2016 - 2028 (USD Million)
Fig. 35 Clinical trial applications & product registration market, 2016 - 2028 (USD Million)
Fig. 36 Regulatory writing & publishing market, 2016 - 2028 (USD Million)
Fig. 37 Legal representation market, 2016 - 2028 (USD Million)
Fig. 38 Others market, 2016 - 2028 (USD Million)
Fig. 39 Product maintenance market, 2016 - 2028 (USD Million)
Fig. 40 Product design & development market, 2016 - 2028 (USD Million)
Fig. 41 Product testing & validation market, 2016 - 2028 (USD Million)
Fig. 42 Training & education market, 2016 - 2028 (USD Million
Fig. 43 Others market, 2016 - 2028 (USD Million)
Fig. 44 U.K. Biotechnology/pharmaceutical services outsourcing market end-use outlook: Segment dashboard
Fig. 45 U.K. Biotechnology/pharmaceutical services outsourcing market: End-use movement analysis
Fig. 46 Pharmaceutical companies market, 2016 - 2028 (USD Million)
Fig. 47 Biotech companies market, 2016 - 2028 (USD Million)
Fig. 48 Strategic Map
Fig. 1 Market research process
Fig. 2 Information procurement
Fig. 3 Primary research pattern
Fig. 4 Primary interviews in Europe
Fig. 5 Market research approaches
Fig. 6 QFD modeling for market share assessment
Fig. 7 Market formulation & validation
Fig. 8 Commodity flow analysis
Fig. 9 U.K. Biotechnology/pharmaceutical services outsourcing market snapshot (2020)
Fig. 10 U.K. Biotechnology/pharmaceutical services outsourcing market segmentation
Fig. 11 Market driver relevance analysis (Current & future impact)
Fig. 12 Pharmaceutical R&D spending, 2015-2024 (USD billion)
Fig. 13 Average cost per new drug development, 2000 - 2011 (USD Million)
Fig. 14 Failure rates in phase transitions during drug development
Fig. 15 Market restraint relevance analysis (Current & future impact)
Fig. 16 Penetration & growth prospect mapping
Fig. 17 Porter’s five forces analysis
Fig. 18 SWOT analysis, by factor (political & legal, economic and technological)
Fig. 19 Reasons behind outsourcing
Fig. 20 Percentage of outsourcing of different functions
Fig. 21 Selection parameters
Fig. 22 Heat map for pricing models opted by competitors
Fig. 23 Companies with affected trials, by size
Fig. 24 Affected trials, by study phase
Fig. 25 COVID-19 trials, 2020
Fig. 26 U.K. Biotechnology/pharmaceutical services outsourcing market stage outlook: Segment dashboard
Fig. 27 U.K. Biotechnology/pharmaceutical services outsourcing market: Service movement analysis
Fig. 28 Consulting market, 2016 - 2028 (USD Million)
Fig. 29 Regulatory compliance market, 2016 - 2028 (USD Million)
Fig. 30 Remediation market, 2016 - 2028 (USD Million)
Fig. 31 Quality management systems consulting market, 2016 - 2028 (USD Million)
Fig. 32 Others market, 2016 - 2028 (USD Million)
Fig. 33 Auditing and assessment market, 2016 - 2028 (USD Million)
Fig. 34 Regulatory affairs market, 2016 - 2028 (USD Million)
Fig. 35 Clinical trial applications & product registration market, 2016 - 2028 (USD Million)
Fig. 36 Regulatory writing & publishing market, 2016 - 2028 (USD Million)
Fig. 37 Legal representation market, 2016 - 2028 (USD Million)
Fig. 38 Others market, 2016 - 2028 (USD Million)
Fig. 39 Product maintenance market, 2016 - 2028 (USD Million)
Fig. 40 Product design & development market, 2016 - 2028 (USD Million)
Fig. 41 Product testing & validation market, 2016 - 2028 (USD Million)
Fig. 42 Training & education market, 2016 - 2028 (USD Million
Fig. 43 Others market, 2016 - 2028 (USD Million)
Fig. 44 U.K. Biotechnology/pharmaceutical services outsourcing market end-use outlook: Segment dashboard
Fig. 45 U.K. Biotechnology/pharmaceutical services outsourcing market: End-use movement analysis
Fig. 46 Pharmaceutical companies market, 2016 - 2028 (USD Million)
Fig. 47 Biotech companies market, 2016 - 2028 (USD Million)
Fig. 48 Strategic Map
